MedPath

Abnormal fibre utilisation in ulcerative colitis in remissio

Not Applicable
Completed
Conditions
lcerative colitis
Ulcerative colitis
Oral and Gastrointestinal - Inflammatory bowel disease
Registration Number
ACTRN12614000271606
Lead Sponsor
Sally James
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
30
Inclusion Criteria

Age over 18 years
Diagnosis of ulcerative colitis, in remission

Healthy control inclusion criteria were age over 18 yrs, absence of bowel disease and absence of medication which affect bowel function and microbiota

Exclusion Criteria

Diagnosis of Crohn's disease, colectomy
Use of any of the following medication within the preceding 4 weeks, due to their effect on bowel and or microbial function:
Sulfasalazine, antibiotics, laxatives, topical rectal therapy, codeine or constipating drugs.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Composite primary outcome; <br>Faecal indices:<br>Faecal daily output, products of fermentation<br>Faecal starch and non-starch polysaccharide output<br>Microbial abundance <br><br>Faecal output was weighed, pH probed and SCFAs and Phenolic compounds measured with high performamce gas chromatography. Freeze dried faecal samples were analysed with commercial enzyme kits for residual fibres. Microbial abundances were tested with quantative polymerase chain reaction and denaturing gradient gel electrophoresis.<br><br>[After 7 days of usual diet (baseline), after each dietary intervention (after 17 days of supplementation with low or high amounts of fibre).]
Secondary Outcome Measures
NameTimeMethod
Clinical indices:<br>Tolerability of dietary supplements with regard to bowel symptoms was recorded on a 4 point Likert scale[At the end of each dietary intervention period (day 17 of each arm)];Whole gut transit time <br>Measured using radio-opaque markers x-rayed in 3 day faecal collection [Measured during the last 3 days of each observed period; baseline control period, and both intervention arms. ]
© Copyright 2025. All Rights Reserved by MedPath